Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Beckman Coulter
| Company | Beckman Coulter |
|---|---|
| Name of instrument | DxC 500i Clinical Analyzer |
| Contact | Shannon Garegnani |
| City, State | Brea, CA |
| Phone | 800-526-3821 |
| Website | |
| Type of instrument | combination chemistry/immunoassay |
| Operational type/Model type | continuous random access/floor standing |
| List price/First year sold in U.S. | —/2025 |
| Targeted hospital bed size/Targeted test volume | —/annual: 50,000–350,000 |
| Company manufactures instrument | yes (also sold by distribution partners) |
| Other models in this family of analyzers | DxC 500 AU, DxC 700 AU, AU5800, Access 2, DxI 600, DxI 9000 |
| No. of units in clinical use in U.S./Outside U.S. (countries) | —/— (worldwide) |
| Dimensions (H × W × D)/Instrument footprint | 48.8 × 100 × 30.3 in./21 sq. ft. |
| Weight empty/Weight fully loaded | 1,430 lbs./— |
| No. of different measured assays onboard simultaneously | — |
| No. of user-definable (open chemistry) channels | — |
| Test throughput per hour/Assay run time | 800 chemistry with ISE, 100 immunoassay/— |
| No. of direct ion-selective electrode channels | — |
| Detection methods | photometry, potentiometry |
| Stat time until completion/specimen throughput for ion-selective electrode | — |
| Stat time until completion/specimen throughput for basic metabolic panel | — |
| Stat time until completion/specimen throughput for complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | — |
| Fully automated microplate immunoassay system | no |
| Methodologies supported | chemiluminescence |
| Separation methodologies | — |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Approximate No. of tests per reagent set/Reagent type | 50–6,744 per pack (varies by assay)/— |
| Reagents refrigerated onboard/Reagents ready to use | yes (4.5°–12°C)/variable; reagent specific |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (open reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/no |
| Walkaway capability/Walkaway duration | yes/168 specimens |
| Design of sample-handling system | rack |
| Uses washable cuvettes/Uses disposable cuvettes | yes (can store up to 88 cuvettes)/no |
| Min.–max. sample volume that can be aspirated at one time | 1–25 µL |
| Min. reaction volume/Min. specimen volume/Min. dead volume | 90 µL/50 µL/80 µL |
| Dedicated pediatric sample cup | no |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/— |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | detection for hemolysis, icterus, lipemia, clots |
| Dilutes patient samples onboard/Susceptibility to carryover | yes (can be programmed to perform dilutions prior to analysis)/— |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | yes |
| Autocalibration/Multipoint calibration supported | yes (calibrants are not stored onboard)/yes |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | 1 day/—/—/1–90 days/— |
| Automatic programmable start/Automatic programmable shutdown | — |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | direct to drain |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Code 39, Code 128, NW7, EAN-13, ISBT 128, Standard 2 of 5)/— |
| Lab can control analyzer from remote computer | yes |
| Instrument can diagnose its own malfunctions | yes (instrument can order malfunctioning parts) |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | onboard/Medicus, Evident, CGM LabDaq, Oracle Health, Clinisys |
| LIS interface provided/Bidirectional interface capability | yes (additional cost)/yes (host query) |
| Modem servicing provided/Service engineer on-site response time | — |
| Mean time between failures | — |
| Average scheduled maintenance time by lab personnel | daily: 9 min.; weekly: 26 min.; monthly: 45 min. |
| Maintenance records kept onboard for user/vendor | yes/no |
| Maintenance training demonstration module onboard | yes |
| Training included with purchase/Avg. time for basic user training | yes (2 training slots)/— (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at vendor site)/— |
| Warranty provided/Cost of annual service contract (24 h/7 d) | — |
| Distinguishing features (supplied by company) | independent and integrated operations, reagent load on the fly, rapid throughput; single point of sample loading, intuitive interface and guided workflows, easy to maintain parts; offers a menu of more than 170 assays for complete disease state management |